ATNM News 12.30 Actinium Pharmaceuticals Inc. (ATNM)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actinium Pharmaceuticals Inc. (ATNM) 12.30 $ATNM

Actinium Pharmaceuticals, Inc. Analyst Report: High Potential Emerging Biopharmaceutical Firm Nearing Phase 3 Trial Commencement for Innovative Cancer Treatments
PR Newswire - Thu Apr 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.

Actinium Announces Further Development of Actimab-A Manufacturing
Business Wire - Mon Apr 07, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A. The new manufacturing process that results in a tenfold improvement of manufacturing yield has been developed by the Company internally in collaboration with IsoTherapeutics. IsoTherapeutics will perform additional experiments to generate documentation necessary for regulatory submissions.

Actinium CEO Interviewed for "Small Stocks: Big Money" Airing on Fox Business and Bloomberg
Business Wire - Thu Apr 03, 12:15PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces the availability of an exclusive interview with its President and CEO, Kaushik J. Dave, Ph.D.

Actinium's shares listed on NYSE MKT to facilitate increased visibility and liquidity
M2 - Thu Mar 27, 5:14AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) revealed on Wednesday that its shares have begun trading as of 26 March 2014 on the NYSE MKT under the symbol "ATNM".

Actinium Commences Trading on NYSE MKT Today under the Symbol ATNM
Business Wire - Wed Mar 26, 8:30AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that its shares have commenced trading today on the NYSE MKT under the symbol "ATNM". The company formerly traded on the OTCQB under the same symbol.

Actinium to Commence Trading on NYSE MKT on March 26, 2014
Business Wire - Tue Mar 25, 9:05AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will commence trading its common shares on the NYSE MKT beginning on March 26, 2014.

Actinium to Present at BioCentury 21st Annual Future Leaders in the Biotech Industry Conference on March 28
Business Wire - Tue Mar 25, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the BioCentury 21st Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 8:30 am Eastern Time.

Actinium to begin trading on NYSE MKT on 26 March 2014
M2 - Tue Mar 25, 4:16AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) disclosed on Monday that it will commence trading on the New York Stock Exchange on 26 March 22014.

Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients
M2 - Tue Mar 25, 4:06AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) said on Monday that it has treated the first patient with Actimab-A drug candidate for newly diagnosed AML patients under its ongoing Phase 1/2 trial.

Actinium to List Common Stock on NYSE MKT
Business Wire - Mon Mar 24, 4:20PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on March 26, 2014. The Company will continue to trade under the symbol "ATNM" but will withdraw its shares from listing on the OTCQB concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.

Actinium Announces Introduction of the New Lot of Lintuzumab into the Clinic
Business Wire - Mon Mar 24, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate manufactured with the new lot of Lintuzumab, the antibody that provides the backbone for Actimab-A. The ongoing Phase 1/2 trial of Actimab-A is in newly diagnosed AML patients over the age of 60 in a single arm multicenter trial.

Actinium to Present at 2nd Annual Sachs Cancer Bio Partnering & Investor Forum
Business Wire - Thu Mar 13, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at New York Academy of Sciences, located at 250 Greenwich St, New York, NY, on Wednesday, March 19, 2014 at 2:45 PM ET.

Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013

Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET.

Actinium to Host Advisory Meeting at the 2014 ASBMT and CIBMTR Conference
Marketwire - Wed Feb 26, 7:08AM CST
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host an advisory meeting with leading bone marrow transplant experts during the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in Grapevine, Texas on Saturday, March 1, 2014. The Company will present an agreement reached with the Food and Drug Administration (FDA) on the design of a single pivotal Phase III trial for approval of Iomab(TM)-B, Actinium's leading drug candidate. The advisory group will discuss the Iomab(TM)-B Phase III trial design, formation of a Scientific Advisory Board for Iomab(TM)-B and logistics of the Phase III trial.

Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.

Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica

Global Radiopharmaceuticals Market Insight Research Report
M2 - Tue Feb 11, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8p2r/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" report to their offering. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly. A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%. This segment is mainly dominated by isotopes like I-131, Sm-153, Re-186, Y-90, and Lu-177. It is expected that over the next 5-6 years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers. The increasing popularity and use of SPECT and PET scans, new and efficient technological equipment, increased awareness about radiopharmaceuticals among physicians and most importantly, the easy availability of radiopharmaceutical from cyclotrons are some of the major factors driving the global radiopharmaceutical market. Inspite of the market for radiopharmaceuticals growing rapidly, there are many challenges, like high cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals. Additionally, there are also some obstacles with regards to the manufacturing of radioisotopes, which need to be addressed to tap the opportunities. The global market for radiopharmaceuticals was estimated to be valued at approximately USD 5.3 billion in 2013. Owing to factors like the increasing adoption rates of PET and SPECT scanners, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons, coupled with significant developments in research and technology, this market is expected to record a CAGR of close to 15% to reach approximately USD 10.6 billion by 2018. Report Highlights: - Global Radio Pharmaceuticals Market Overview by Region - Target Patient Base by Region - Radiopharmaceuticals Market Regulation for US, Europe & Canada - Radioisotopes Used in Radiopharmaceuticals - Radiopharmaceutical Clinical Pipeline Insight - Profile of 87 Radiopharmaceuticals Drugs in Clinical Phase Companies Mentioned - AREVA Med - Actinium Pharmaceuticals - Avid Radiopharmaceuticals - Bayer HealthCare Pharmaceuticals - Cardinal Health - GE Healthcare - Immunomedics - Ion Beam Applications - Lantheus Medical Imaging - Lantheus Medical Imaging - Merck & Co - Navidea - Nordion - PETNET Solutions (Siemens Healthcare Global) For more information visit http://www.researchandmarkets.com/research/px8p2r/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Actinium Presenting at the 16th Annual BIO CEO & Investor Conference Today at 1:30 pm ET
Business Wire - Tue Feb 11, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 1:30 pm ET at the 16th Annual BIO CEO & Investor Conference. Dr. Kaushik J. Dave, President and CEO, will present a corporate update.

Actinium to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company" , a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 16th Annual BIO CEO & Investor Conference from February 10th to 11th, 2014. Dr. Dave will present an overview of the company on Tuesday, February 11, 2014 at 1:30 pm ET.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 56

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 145

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 127

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 125

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 106

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 53

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 40

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 0

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading

Top 5 Most Recently Viewed Articles

SimSpace's Stack Optimizer: Revolutionizing IT and Security Performance

Updated Category News Views 218

Introducing the Cutting-Edge Stack Optimizer SimSpace, a leader renowned for creating high-fidelity simulated environments, has unveiled its latest innovation: Stack Optimizer. This groundbreaking tool is designed to empower organizations to rigorously evaluate, test, and enhance their security and IT infrastructure. By leveraging sophisticated simulation techniques,...

Continue Reading
Datavault AI Transforms Comedy with Innovative Digital Solutions

Updated Category News Views 187

Revolutionizing Live Comedy with Digital Technology In an exciting collaboration, Datavault AI Inc. (NASDAQ: DVLT), renowned for its data monetization and digital engagement technologies, is partnering with Rodney's Comedy Club. This partnership marks a significant transformation in the way audiences and performers engage during live entertainment events. With the rollout...

Continue Reading
Hydreight Technologies Highlights Q3 Growth and Upcoming Plans

Updated Category News Views 169

Hydreight Technologies Overview and Corporate Update Hydreight Technologies Inc. is continuously advancing as it underscores its significant corporate momentum following a recent investor webinar and the release of Q3 financial results. This update not only reflects currently available information but also outlines the path forward, especially highlighting the Company’s...

Continue Reading
Enhancing Culinary Experiences for Autistic Students at School

Updated Category News Views 210

Shrub Oak International School's Renovated Kitchen Shrub Oak International School proudly announces the finished renovation of its kitchen, designed to cater to the unique nutritional and developmental needs of autistic children, adolescents, and young adults. This upgraded space not only enhances meal preparation but also acts as a vital teaching tool, equipping students...

Continue Reading
Red Stone Equity Partners Achieves Remarkable $1.43 Billion Milestone

Updated Category News Views 307

Red Stone Equity Partners Achieves Milestone in Affordable Housing Investments Red Stone Equity Partners LLC, a premier real estate investment firm, has announced significant achievements in affordable housing investment. In 2024, the company raised an unprecedented $1.43 billion from various limited partners. This monumental achievement highlights Red Stone Equity's...

Continue Reading